alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › memory-clinic

memory-clinic

8 studies tagged memory-clinic, dated 2024-03-14 to 2025-08-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients 2025-08-01
  2. Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform 2025-03-27
  3. Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients 2025-03-06

Studies

8 studies carry this tag.

Date range

2024 to 2025

Top journals

  • Alzheimer's research & therapy 4
  • Journal of neurochemistry 1
  • Journal of neurology 1
  • Nature communications 1
  • Scientific reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of neurochemistry 2025-08-01 Biomarkers

    Alzheimer's disease (AD) is characterized by brain protein depositions, impaired synaptic transmission, and progressive cognitive decline.

  2. Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy 2025-03-27 Biomarkers

    Plasma p-tau217 shows excellent results for detecting amyloid pathology at brain level in a clinical setting with an AUC of 0.95.

  3. Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Scientific reports 2025-03-06 Biomarkers

    We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions.

  4. Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer's disease diagnosis in a memory clinic cohort

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of neurology 2025-01-23 Biomarkers

    Plasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer's disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have been performed in research cohorts, limiting their generalizability.

  5. Short-term variability of Alzheimer's disease plasma biomarkers in a mixed memory clinic cohort

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer's research & therapy 2025-01-21 Biomarkers

    We found low intra-individual variability, robust to various factors, appropriate to capture individual changes in AD BBMs, while moderate inter-individual variability may give rise to caution in diagnostic contexts.

  6. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2024-07-06 Biomarkers

    Potential DMT candidates at Butler MAP (n = 50), primarily diagnosed with mild cognitive impairment (n = 29 [58%]) or mild dementia (21 [42%]), were predominantly Aβ-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab.

  7. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's research & therapy 2024-05-16 Biomarkers

    Plasma NfL and GFAP predict cognitive decline in a similar manner to traditional imaging techniques in amyloid-positive MCI patients.

  8. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Nature communications 2024-03-14 Biomarkers

    Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer's disease.

All topic tags with their study counts